Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medmira ( (TSE:MIR) ) has shared an update.
MedMira reported first-quarter fiscal 2026 results marked by Health Canada approval of its Reveal TP rapid syphilis antibody test, enabling nationwide deployment through provincial validations and complementing its existing HIV and dual HIV/TP products. The company advanced its Multiplo Complete Syphilis (TP/nTP) Antibody Test program, moving into a second phase of Canadian clinical trials following strong sensitivity and specificity data published in BMC Infectious Diseases, positioning the test as a tool to support antimicrobial stewardship and reduce healthcare costs. In parallel, MedMira is working with partners to accelerate commercialization of its MiROQ quantitative diagnostic platform, integrating AI for faster, more reliable diagnostics and broadening its future product and market reach. Financially, the quarter showed modest revenue of $54,208 and a narrowed net loss of $813,134 versus the prior year, driven largely by lower operating expenses, alongside a slight decline in assets and an increase in liabilities, underscoring the company’s continued investment phase in product development and regulatory advancement.
The most recent analyst rating on (TSE:MIR) stock is a Hold with a C$0.07 price target. To see the full list of analyst forecasts on Medmira stock, see the TSE:MIR Stock Forecast page.
Spark’s Take on TSE:MIR Stock
According to Spark, TipRanks’ AI Analyst, TSE:MIR is a Neutral.
Medmira’s overall stock score is primarily impacted by its poor financial performance, characterized by negative profitability and weak balance sheet. Technical analysis and valuation also contribute to the low score, with bearish momentum and unattractive valuation metrics.
To see Spark’s full report on TSE:MIR stock, click here.
More about Medmira
MedMira Inc., listed on the TSX Venture Exchange, operates in the medical diagnostics industry, specializing in rapid point-of-care tests for infectious diseases such as HIV and syphilis. Its portfolio is built on the company’s proprietary RVF Technology platform, and it is expanding into advanced diagnostic systems, including the MiROQ quantitative testing technology with potential applications in cancer diagnostics, targeting both public health and clinical markets in Canada and beyond.
Average Trading Volume: 94,202
Technical Sentiment Signal: Sell
Current Market Cap: C$48.84M
See more data about MIR stock on TipRanks’ Stock Analysis page.